Short answers, pulled from the story.
Genentech was founded in January 1976 by venture capitalist Robert Swanson and biochemist Herbert Boyer. They invested five hundred dollars each to capitalize the company after a meeting at the University of California laboratory.
The U.S. Food and Drug Administration approved synthetic insulin known as Humulin in 1982 through a partnership with Eli Lilly and Company. This product became the first genetically engineered human therapeutic ever approved.
F. Hoffmann-La Roche AG acquired a majority stake in Genentech in 1990. The Swiss pharmaceutical giant eventually bought all remaining shares for approximately forty-six point eight billion dollars in March 2009.
Corporate headquarters remain located in South San Francisco, California. Manufacturing facilities operate in Vacaville, Oceanside, and Hillsboro, Oregon.
Genentech agreed to pay two hundred million dollars to UCSF in November 1999 to conclude the nine-year-old patent dispute. A jury ruled that the university's patent was valid in July 1999 before the settlement distributed funds to inventors and research efforts.